Trial Profile
A randomized (1:1), double-blind, parallel, placebo-controlled exploratory pilot study to evaluate the safety, pharmacokinetics and efficacy of systemic (po) application of MP1032 in patients with moderate to severe chronic plaque psoriasis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs MP 1032 (Primary)
- Indications Plaque psoriasis
- Focus Adverse reactions; Pharmacokinetics
- Sponsors MetrioPharm
- 20 Mar 2017 Status changed from active, no longer recruiting to completed.
- 14 Mar 2017 Top-line results from this study published in a MetrioPharm media release.
- 19 Dec 2016 Status changed from recruiting to active, no longer recruiting.